The US Food and Drug Administration (FDA) has granted approval to Synaptive Medical‘s ImageDrive Pro, an informatics platform, which integrates the company’s existing BrightMatter technologies.
The integration is said to be necessary to facilitate a standardised approach to capturing data on a health informatics platform that performs analytics on a large scale, while ensuring patient privacy and paving the way for precision medicine.
Synaptive Medical’s informatics platform is claimed to offer a quick, patient-centric and unified experience for interdisciplinary review.
Its quality assurance model also caters to the requirement for surgical planning and visualisation of a patient’s unique fibre tracts.
The platform addresses the growing need for a scalable, automated and confidential data exchange between clinical and research environments with the adoption of initiatives like the Human Genome Project, Cancer Moonshot, and the recent White House’s announcement to accelerate precision medicine.
It will assist the researchers with automated data distribution, de-identification, and extensibility using well-established protocols.
Data is easily de-identified and can be shared with collaborators using well-established secure mechanisms.
Informatics commercial head Brian Oswald said: "Imaging data offers a ubiquitous snapshot that can quantify a patient’s response to various treatment and therapy protocols.
"With data driven insights, we have the opportunity to accelerate quality care with efficient resource utilisation, ultimately driving positive outcomes."
Imaging Informatics will allow clinicians to achieve an optimal patient-centered, value-based model of care focused on improving outcomes.
Synaptive Medical is also looking to develop its user’s data environments by aggregating with third party sources such as pathology reports, EMR and genomic data.
Image: BrightMatter Plan. Photo: courtesy of Synaptive Medical, Inc.